Literature DB >> 15161974

Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta.

Bibiana Bielekova1, Nancy Richert, Thomas Howard, Gregg Blevins, Silva Markovic-Plese, Jennifer McCartin, Joseph A Frank, Jens Würfel, Joan Ohayon, Thomas A Waldmann, Henry F McFarland, Roland Martin.   

Abstract

Identifying effective treatment combinations for MS patients failing standard therapy is an important goal. We report the results of a phase II open label baseline-to-treatment trial of a humanized monoclonal antibody against CD25 (daclizumab) in 10 multiple sclerosis patients with incomplete response to IFN-beta therapy and high brain inflammatory and clinical disease activity. Daclizumab was very well tolerated and led to a 78% reduction in new contrast-enhancing lesions and to a significant improvement in several clinical outcome measures.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15161974      PMCID： PMC423259          DOI： 10.1073/pnas.0402653101

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


  15 in total

1.  A pilot study of recombinant insulin-like growth factor-1 in seven multiple sderosis patients.

Authors:  J A Frank; N Richert; B Lewis; C Bash; T Howard; R Civil; R Stone; J Eaton; H McFarland; T Leist
Journal:  Mult Scler       Date:  2002-02       Impact factor: 6.312

2.  Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand.

Authors:  B Bielekova; B Goodwin; N Richert; I Cortese; T Kondo; G Afshar; B Gran; J Eaton; J Antel; J A Frank; H F McFarland; R Martin
Journal:  Nat Med       Date:  2000-10       Impact factor: 53.440

3.  Method for quantification of brain, ventricular, and subarachnoid CSF volumes from MR images.

Authors:  C DeCarli; J Maisog; D G Murphy; D Teichberg; S I Rapoport; B Horwitz
Journal:  J Comput Assist Tomogr       Date:  1992 Mar-Apr       Impact factor: 1.826

Review 4.  Clinical scales for multiple sclerosis.

Authors:  B Sharrack; R A Hughes
Journal:  J Neurol Sci       Date:  1996-01       Impact factor: 3.181

5.  Prospective study on the relationship between infections and multiple sclerosis exacerbations.

Authors:  D Buljevac; H Z Flach; W C J Hop; D Hijdra; J D Laman; H F J Savelkoul; F G A van Der Meché; P A van Doorn; R Q Hintzen
Journal:  Brain       Date:  2002-05       Impact factor: 13.501

6.  Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration.

Authors:  Robert B Nussenblatt; Darby J S Thompson; Zhuqing Li; Chi Chao Chan; Jan S Peterson; Randy R Robinson; Richard S Shames; Sudha Nagarajan; Meina Tao Tang; Michelle Mailman; Gisela Velez; Chandra Roy; Grace A Levy-Clarke; Eric B Suhler; Ali Djalilian; Hatice Nida Sen; Shadi Al-Khatib; Roxana Ursea; Sunil Srivastava; Allison Bamji; Susan Mellow; Pushpa Sran; Thomas A Waldmann; Ronald R Buggage
Journal:  J Autoimmun       Date:  2003-11       Impact factor: 7.094

7.  Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group.

Authors:  D W Paty; D K Li
Journal:  Neurology       Date:  1993-04       Impact factor: 9.910

8.  Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).

Authors:  J F Kurtzke
Journal:  Neurology       Date:  1983-11       Impact factor: 9.910

9.  Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials.

Authors:  Angela C Webster; E Geoffrey Playford; Gail Higgins; Jeremy R Chapman; Jonathan C Craig
Journal:  Transplantation       Date:  2004-01-27       Impact factor: 4.939

10.  A controlled trial of natalizumab for relapsing multiple sclerosis.

Authors:  David H Miller; Omar A Khan; William A Sheremata; Lance D Blumhardt; George P A Rice; Michele A Libonati; Allison J Willmer-Hulme; Catherine M Dalton; Katherine A Miszkiel; Paul W O'Connor
Journal:  N Engl J Med       Date:  2003-01-02       Impact factor: 91.245
View more
  96 in total

1.  Intrathecal effects of daclizumab treatment of multiple sclerosis.

Authors:  B Bielekova; N Richert; M L Herman; J Ohayon; T A Waldmann; H McFarland; R Martin; G Blevins
Journal:  Neurology       Date:  2011-11-09       Impact factor: 9.910

Review 2.  Natural killer cells and their receptors in multiple sclerosis.

Authors:  Gurman Kaur; John Trowsdale; Lars Fugger
Journal:  Brain       Date:  2012-06-25       Impact factor: 13.501

Review 3.  T-cell based immunotherapy in experimental autoimmune encephalomyelitis and multiple sclerosis.

Authors:  Kate O'Brien; Bruno Gran; Abdolmohamad Rostami
Journal:  Immunotherapy       Date:  2010-01       Impact factor: 4.196

4.  Monoclonal antibodies in multiple sclerosis treatment: current and future steps.

Authors:  Claire L Helliwell; Alasdair J Coles
Journal:  Ther Adv Neurol Disord       Date:  2009-07       Impact factor: 6.570

5.  Innovative monoclonal antibody therapies in multiple sclerosis.

Authors:  Ralf A Linker; Bernd C Kieseier
Journal:  Ther Adv Neurol Disord       Date:  2008-07       Impact factor: 6.570

Review 6.  Neuroimmunotherapies Targeting T Cells: From Pathophysiology to Therapeutic Applications.

Authors:  Stefan Bittner; Heinz Wiendl
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

7.  Long-term daclizumab therapy in relapsing-remitting multiple sclerosis.

Authors:  Monica A Rojas; Noel G Carlson; Thomas L Miller; John W Rose
Journal:  Ther Adv Neurol Disord       Date:  2009-09       Impact factor: 6.570

Review 8.  T-cell exhaustion: understanding the interface of chronic viral and autoinflammatory diseases.

Authors:  Eoin F McKinney; Kenneth Gc Smith
Journal:  Immunol Cell Biol       Date:  2016-11       Impact factor: 5.126

9.  Foxp3+ CD25- CD4 T cells constitute a reservoir of committed regulatory cells that regain CD25 expression upon homeostatic expansion.

Authors:  Santiago Zelenay; Thiago Lopes-Carvalho; Iris Caramalho; Maria Francisca Moraes-Fontes; Manuel Rebelo; Jocelyne Demengeot
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-07       Impact factor: 11.205

Review 10.  Disease-modifying therapy of pediatric multiple sclerosis.

Authors:  Tanuja Chitnis
Journal:  Neurotherapeutics       Date:  2013-01       Impact factor: 7.620
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.